Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ibuprofen; pseudoephedrine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ibuprofen; pseudoephedrine HCl | DRUG | - |
Inclusion Criteria: * Subject has nighttime bedwetting * between the 5th and 95th percentiles for weight based on age and gender * has a minimum of eight wet nights per 14 days of the baseline period * healthy with no symptoms of any other complicating disease as determined by medical history revie...
Ibuprofen; pseudoephedrine is being studied for the treatment of enuresis, commonly known as nighttime bedwetting. It is a small molecule combination drug developed by Johnson & Johnson. The research focuses on whether the combination is more effective than either drug alone in managing this condition.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of the ibuprofen; pseudoephedrine combination. The company sponsored the clinical research evaluating this fixed-dose combination for enuresis.
Ibuprofen; pseudoephedrine is in Phase 2 clinical development. The only listed trial for this combination is a completed Phase 2 study. It is an investigational product and has not been approved by the FDA for the treatment of enuresis.
Ibuprofen; pseudoephedrine has been evaluated in one completed clinical trial, NCT00240812. The study was titled "A Study to Determine if Ibuprofen in Combination With Pseudoephedrine HCl is More Effective Than Each Drug Alone in the Treatment of Nighttime Bedwetting." It enrolled 318 participants aged 6 years and older.